Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
7.40    0.00 (0.00%)
Bid:
7.30
Ask:
7.50
Spread: 0.20 (2.74%)
Market Cap: £3.24m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

Disposal

3 May 2016 12:00

RNS Number : 0664X
Feedback PLC
03 May 2016
 

3 May 2016

 

Feedback plc

("Feedback" or the "Company")

 

Disposal

 

Feedback plc (AIM: FDBK), the medical imaging software company is pleased to announce that it has agreed to sell its 50% equity interest in Stone Checker Software Ltd ('Stone Checker') to Free Association Books Limited, a company connected to one of Feedback's directors, Trevor Brown, for a cash consideration of £46,000 (the "Disposal").

 

Feedback invested £1,000 in Stone Checker in July 2015 and subsequently licensed its TexRAD software to Stone Checker for exclusive use in urolithiasis (kidney stones). On 28 September 2015, Feedback announced the intention to develop a product incorporating TexRAD for kidney stones. It was further stated that the vision of Stone Checker was to develop a composite risk stratification software product incorporating TexRAD CT texture analysis with other known clinical markers. This integrated product could potentially assist urologists and radiologists to provide better patient management and treatment decisions for improved patient outcomes.

 

Stone Checker is making good progress and is reaching the stage where it will require substantial additional investment. Feedback has already announced that it is committing significant resources in developing a lung cancer stratification tool in conjunction with Alliance Medical Group. Accordingly, although urolithiasis could be an exciting application for TexRAD, the directors of Feedback are of the opinion that they should focus investment in TexRAD's use in oncology. The sale of the equity interest in Stone Checker will generate a profit of £45,000 before expenses. Feedback will continue to receive royalty and licence payments should Stone Checker achieve commercial success. The sale proceeds will be used by Feedback for general corporate purposes.

 

Stone Checker is currently a pre-revenue company which made a loss before tax for the period ending 29 February 2016 of £154.

 

Related Party Transaction

 

Trevor Brown is a director and substantial shareholder in Feedback. Dr Balaji Ganeshan is a director of Stone Checker representing Feedback and is expected to remain a director of both Feedback and Stone Checker after the Disposal. Accordingly, the Disposal constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies ("AIM Rules"). The other three directors of Feedback have no direct involvement in Stone Checker and are not related to the purchaser of Feedback's holding and are therefore deemed to be independent under the AIM Rules for the purposes of considering the related party transaction (the "Independent Directors"). The Independent Directors, having consulted with Allenby Capital Limited, the Company's nominated adviser, consider that the terms of the disposal are fair and reasonable insofar as the Company's shareholders are concerned.

 

For further information, contact:

Feedback plc

Tom Charlton / Mike Hayball

Tel: 01954 718072

 

Allenby Capital Limited (Nominated Adviser and Joint Broker)

Simon Clements / James Thomas

Tel: 020 3328 5656

 

Peterhouse Corporate Finance Ltd (Joint Broker)

Lucy Williams / Duncan Vasey 

Tel: 020 7469 0936

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISAJMMTMBAMBFF
Date   Source Headline
8th Jun 20171:15 pmRNSCCI Exclusive Distributor Agreement with Korea ISG
8th Jun 20171:11 pmRNSDirectorate Change
1st Jun 20179:23 amRNSTotal Voting Rights
30th May 20174:38 pmRNSFurther re. Notice of Resignation of Director
18th May 20177:00 amRNSProgress with CE Mark and trading update
12th May 201711:57 amRNSHolding(s) in Company
2nd May 20177:00 amRNSNotice of Resignation of Director
26th Apr 20177:00 amRNSIssue of Equity
30th Mar 20177:00 amRNSLetter of Intent signed and trading update
3rd Mar 20177:00 amRNSAppointment of Joint Broker
20th Feb 20177:00 amRNSHalf-year Report
23rd Jan 20171:28 pmRNSRe: Media Articles
30th Nov 20165:00 pmRNSTotal Voting Rights
24th Nov 201612:44 pmRNSDirector/PDMR Shareholding
23rd Nov 20161:20 pmRNSIssue of Equity & Director / PDMR Shareholding
23rd Nov 201610:33 amRNSResult of AGM
16th Nov 20167:00 amRNSAttendance at RSNA 2016
19th Oct 20163:17 pmRNSRe: Directorate
19th Oct 20167:00 amRNSFinal results for the year ended 31 May 2016
21st Sep 201612:30 pmRNSTrading Update
28th Jul 20161:31 pmRNSCollaboration with Future Processing
1st Jun 201612:30 pmRNSAppointment of Non-Executive Chairman
3rd May 201612:00 pmRNSDisposal
2nd Mar 20167:00 amRNSChange of Nominated Adviser
22nd Feb 20167:00 amRNSInterim Results for the 6 months ended 30 Nov 2015
30th Nov 20152:59 pmRNSResult of AGM
23rd Nov 20157:00 amRNSTexRAD Update
6th Nov 20157:01 amRNSDirectorate Change
6th Nov 20157:00 amRNSFinal Results
8th Oct 20157:00 amRNSStrategy Update
6th Oct 20159:45 amRNSNHS publication on potential application of TexRAD
5th Oct 20157:00 amRNSTexRAD Prostate Cancer Product Development
28th Sep 20157:00 amRNSLicence of TexRAD to Stone Checker
9th Sep 20157:00 amRNSFirst sale of TexRAD in China
31st Jul 20157:00 amRNSTotal Voting Rights
20th Jul 20157:00 amRNSStudy Results
9th Jul 20158:39 amRNSExercise of Options
6th Jul 20152:08 pmRNSIssue of Equity
30th Jun 20157:00 amRNSTotal Voting Rights
12th Jun 20157:00 amRNSFirst server sale of TexRAD in Canada
4th Jun 20159:56 amRNSStmnt re Share Price Movement
3rd Jun 20157:00 amRNSIssue of Equity
15th May 20157:00 amRNSCollaboration with University of Texas
11th May 20153:09 pmRNSPreliminary results from the Oxford Stone Group
29th Apr 20157:00 amRNSDrug Trial and Trading Update
28th Apr 20157:00 amRNSCollaboration with Princess Alexandra Hospital, AU
27th Apr 20157:00 amRNSFirst sale of TexRAD in South Korea
23rd Apr 201512:15 pmRNSStmnt re Share Price Movement
20th Apr 20157:00 amRNSAdoption of TexRAD research software
13th Apr 20157:00 amRNSCollaboration with the Oxford Stone Group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.